X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Elder Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ELDER PHARMA ALEMBIC PHARMA/
ELDER PHARMA
 
P/E (TTM) x 29.6 -0.2 - View Chart
P/BV x 6.8 0.1 6,698.2% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALEMBIC PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
ELDER PHARMA
Jun-14
ALEMBIC PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs792380 208.3%   
Low Rs443188 235.6%   
Sales per share (Unadj.) Rs167.0491.2 34.0%  
Earnings per share (Unadj.) Rs38.2-3.2 -1,199.5%  
Cash flow per share (Unadj.) Rs42.014.4 291.4%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.9376.5 22.5%  
Shares outstanding (eoy) m188.5220.54 917.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.70.6 639.3%   
Avg P/E ratio x16.2-89.3 -18.1%  
P/CF ratio (eoy) x14.719.7 74.6%  
Price / Book Value ratio x7.30.8 964.0%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,3835,833 1,995.1%   
No. of employees `000NANA-   
Total wages/salary Rs m4,2142,179 193.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m31,48710,089 312.1%  
Other income Rs m55257 21.5%   
Total revenues Rs m31,54210,346 304.9%   
Gross profit Rs m10,060-792 -1,270.3%  
Depreciation Rs m722361 199.9%   
Interest Rs m372,756 1.3%   
Profit before tax Rs m9,356-3,653 -256.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m2,160125 1,726.1%   
Profit after tax Rs m7,194-65 -11,008.9%  
Gross profit margin %31.9-7.8 -407.0%  
Effective tax rate %23.1-3.4 -673.9%   
Net profit margin %22.8-0.6 -3,527.5%  
BALANCE SHEET DATA
Current assets Rs m15,0669,240 163.0%   
Current liabilities Rs m7,6749,998 76.8%   
Net working cap to sales %23.5-7.5 -312.6%  
Current ratio x2.00.9 212.4%  
Inventory Days Days6746 144.6%  
Debtors Days Days4160 67.8%  
Net fixed assets Rs m8,23710,124 81.4%   
Share capital Rs m377206 183.3%   
"Free" reserves Rs m15,4165,582 276.2%   
Net worth Rs m16,0057,734 207.0%   
Long term debt Rs m04,889 0.0%   
Total assets Rs m24,59422,882 107.5%  
Interest coverage x255.2-0.3 -78,464.8%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.30.4 290.4%   
Return on assets %29.411.8 250.0%  
Return on equity %44.9-0.8 -5,319.3%  
Return on capital %58.722.3 263.0%  
Exports to sales %55.73.0 1,834.2%   
Imports to sales %10.40.4 2,440.7%   
Exports (fob) Rs m17,551307 5,724.3%   
Imports (cif) Rs m3,28343 7,617.2%   
Fx inflow Rs m17,811307 5,809.0%   
Fx outflow Rs m5,318125 4,244.2%   
Net fx Rs m12,493181 6,890.5%   
CASH FLOW
From Operations Rs m9,30411,754 79.2%  
From Investments Rs m-3,105-561 553.9%  
From Financial Activity Rs m-1,959-6,762 29.0%  
Net Cashflow Rs m4,2404,432 95.7%  

Share Holding

Indian Promoters % 74.1 39.6 187.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 7.5 38.7%  
FIIs % 9.1 16.8 54.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 36.1 38.5%  
Shareholders   49,328 16,479 299.3%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   NATCO PHARMA  PLETHICO PHARMA  FDC LTD.  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS